Podcasts

Updated REMS for Rosiglitazone-containing Medicines

Published Online: Friday, October 21, 2011

Listen as Catherine Chew, a pharmacist in the FDA’s Division of Drug Information, describes the restrictions for prescribing and using rosiglitazone-containing medicines, including type 2 diabetes medications Avandia, Avandamet, and Avandaryl.

Click here to access the podcast.

User Comment(s)

Comment(s)

Your comments are valuable to us. Thank you.

Sorry, you must be logged in and registered to post a comment.

To login, click here. To register, click here.

Related Resources

Pharmacy Management

Risk Evaluation and Mitigation Strategies

Assessing a REMS Strategy: Keep It Simple and Responsible

FDA Announces New REMS for Drugs to Treat Low Platelet Counts

Ten REMS Throw Retirement Party

Impact of Risk Evaluation and Mitigation Strategies in Oncology

Dasatinib and the Risk of Pulmonary Arterial Hypertension

Concentration of Popular Flu Drug Lowered

FDA Targets Prescription Drug Abuse with New REMS

FDA Approves REMS for Actiq and Fentora